Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 03/06/2019
Entire Document
 


SERES THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

 

     Year Ended December 31,  
     2018     2017     2016  

Revenue:

      

Collaboration revenue - related party

   $ 26,917     $ 32,100     $ 21,766  

Grant revenue

     1,350       —         —    
  

 

 

   

 

 

   

 

 

 

Total revenue

     28,267       32,100       21,766  

Operating expenses:

      

Research and development expenses

   $ 95,955       89,455       81,989  

General and administrative expenses

     32,596       34,040       32,616  
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     128,551       123,495       114,605  
  

 

 

   

 

 

   

 

 

 

Loss from operations

     (100,284     (91,395     (92,839
  

 

 

   

 

 

   

 

 

 

Other income (expense):

      

Interest income (expense), net

     1,172       1,590       1,260  

Other income

     170       425       —    
  

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     1,342       2,015       1,260  
  

 

 

   

 

 

   

 

 

 

Net loss

   $ (98,942     (89,380     (91,579

Net loss per share attributable to common stockholders, basic and diluted

   $ (2.43   $ (2.21   $ (2.30
  

 

 

   

 

 

   

 

 

 

Weighted average common shares outstanding, basic and diluted

     40,743,492       40,449,410       39,846,928  
  

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss):

      

Unrealized gain (loss) on investments, net of tax of $0

     146       3       (179
  

 

 

   

 

 

   

 

 

 

Total other comprehensive income (loss)

     146       3       (179
  

 

 

   

 

 

   

 

 

 

Comprehensive loss

   $ (98,796   $ (89,377   $ (91,758
  

 

 

   

 

 

   

 

 

 

IR or PR Contact:

Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467

Vice President, Investor Relations and Corporate Communications

ctanzi@serestherapeutics.com

###


© Seres Therapeutics. All Rights Reserved.